Thomas E. Hutson, D.O., Pharm.D., FACP, is the director of the genitourinary oncology program and co-director of the Center of Excellence for Texas Oncology in the Charles A. Sammons Cancer Center at Baylor University Medical Center; and co-chair of genitourinary research for US Oncology. In addition, he is a professor of medicine at Texas A&M Health Science Center College of Medicine.
Dr. Hutson's main research interests focus on improving outcomes in patients with renal cell carcinoma through the use of novel and targeted agents. Toward this end, he has served as the principal investigator for multiple clinical trials investigating novel therapies in renal cell carcinoma, bladder cancer, and prostate cancer. His research has resulted in over one hundred fifty publications including chapters in medical textbooks on prostate cancer and renal cell carcinoma.
Dr. Hutson received a bachelor's degree in pharmacy from Ohio Northern University in 1993 and in 1997 he obtained the doctor of osteopathic medicine degree from Ohio University College of Osteopathic Medicine. He completed his internship, internal medicine residency, and fellowships in experimental therapeutics and hematology/medical oncology in 2003 at The Cleveland Clinic Foundation. In 2002, Dr. Hutson received his doctor of pharmacy degree, with high distinction, from Ohio Northern University.
Accolades & Memberships:
As a internationally recognized opinion leader in the field of genitourinary oncology, Dr. Hutson serves on the editorial boards of Clinical Prostate Cancer, Clinical Genitourinary Cancer, Kidney Cancer Journal, Expert Review of Anticancer Therapy, Cure, Cancer.Net, and MedTrust and is a reviewer for several other journals, including Cancer, Lancet, and Lancet Oncology.
Faith, and the relationship between religion and medicine, has been of particular importance to Dr. Hutson, especially in the area of end of life (EOL) care. To further increase his own knowledge in this subject he has enrolled in the master of theology (ThM) program at the prestigious Dallas Theological Seminary where he is working with the academic dean on curriculum to improve education of clergy and health care providers. Dr. Hutson also serves as the medical director for Holy Savior Hospice in Dallas, Texas.
Dr. Hutson is married and has two sons.
Current optimal chemotherapy for advanced urothelial cancer.
Expert Review of Anticancer Therapy, 2008
A novel multitargeted tyrosine kinase inhibitor.
Current Oncology Report, 2007
Management of recurrent testicular germ cell tumors.
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
Novel agents for urothelial cancer: review
British Journal of Urology International, 2007
Phase I trial of PEG-Intron and rIL-2 in patients with metastatic renal cell carcinoma
Cancer Chemotherapy and Pharmacology, 2007
Phase II trial of capecitabine and rHU-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy and moderate toxicity.
Urology Oncology, 2007
Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma.
New England Journal of Medicine, 2007
Recent advances in the therapy of renal cancer.
Expert Opinion on Biological Therapy, 2007
Renal Cell Carcinoma: Recent Advances.
The Cancer Journal
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma – a phase III overview.
Expert Review of Anticavity Therapy, 2007
Targeted therapy for renal cell carcinoma: A new treatment paradigm
Baylor Health Care Center Proceedings, 2007
The evolving role of novel targeted agents in renal cell carcinoma.
Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs)
New England Journal of Medicine
A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
Clinical Genitourinary Cancer
Phase I trial of phenoxodiol delivered by continuous intravenous infusion.
Annals of Oncology, 2006
Problems with randomized discontinuation design.
Journal of Clinical Oncology, 2006
Systemic Chemotherapy for Urothelial Cancer.
Clinical Genitourinary Cancer, 2006
Treatment of Patients with Metastatic Renal Cell Carcinoma: A RAND appropriateness panel